The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The antibody was designed and developed at Abzena’s Cambridge, UK,
Expanding US operations to address the increased demand for API development and manufacturing
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
Subscribe To Our Newsletter & Stay Updated
